Median ABR for each dose cohort during once-weekly subcutaneous administration of emicizumab. (A) Bleeding events at any site. (B) Joint bleeding events. All data collected after dose up-titrations were excluded; the number of patients for this summary was 6 per cohort. Cohort 1 included 4 patients with and 2 without inhibitors at study enrollment and data cutoff; cohort 2 included 4 patients with and 2 without inhibitors at study enrollment, and 3 patients with and 2 without inhibitors at data cutoff; cohort 3 included 3 patients with and 3 without inhibitors at study enrollment, and 3 patients with and 2 without inhibitors at data cutoff.